Shaanxi Of China Agrees To Buyout By U.S. Biostar For $9.6 Million
This article was originally published in PharmAsia News
Executive Summary
China's Shaanxi Weinan Huaren Pharmaceuticals, a private company, has agreed to be acquired by U.S.-based Biostar Pharmaceuticals for $9.6 million